期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

利妥昔单抗联合CHOP治疗非霍奇金淋巴瘤的现状(文献综述)

下载PDF
导出
摘要 非霍奇金淋巴瘤（non-Hodgkin＇s lymphoma,NHL）是目前发病率增长速度最快的恶性肿瘤,有90%以上淋巴瘤为NHL。传统的治疗方法以长春新碱、环磷酰胺、泼尼松、阿霉素（CHOP）方案为主。RTX（rituximab,RTX）是特异性针对B淋巴细胞（CD20）的人鼠嵌合单克隆抗体,在1997年获美国食品和药品管理局（FDA）批准用于治疗人类恶性、
作者 于慧杰 江其生
机构地区 第二炮兵总医院中心实验室
出处 《放射免疫学杂志》 CAS 2011年第3期276-278,共3页 Journal of Radioimmanology
关键词 非霍奇金淋巴瘤 治疗方法 利妥昔单抗 文献综述 CHOP 美国食品和药品管理局 LYMPHOMA 嵌合单克隆抗体
分类号 R733.1 [医药卫生—肿瘤]
  • 相关文献

参考文献19

  • 1Torres-Garcla E, Ferro-Flores G, Arteaga de Murphy C, et al. Bioki- hellos and dosimetry of 188Re-anti-CD20 in patients with non-Hodgkin' s lymphoma: prelimitmry experience [ J ]. Arch Med Res, 2008,39 ( 1 ) : 100-109.
  • 2Jacobs SA, Foon KA. The expanding role of rituxdmab and radioim- munotherapy in the treatment of B-cell lymphomas[ J ]. Expert Opin Biol Ther, 2007,7 ( 11 ) : 1749-1762,.
  • 3Macardle PJ, Nicholson IC. CD20 [ J ]. J Biol Regul Homeost A- gents, 2002,16(2) :136-138.
  • 4Huhln LE, Hausner MA, Huhin PM, et al. CIY20 (pan-B cell) an- tigen is expressed at a low level on a subpopulation of human T lympho- cytes[J]. Cytometry,1993,14(2) :196-204.
  • 5Coiffier B. Rituximab therapy in malignant 1 ymphoma[ J ]. Oneo- gene, 2007, 26(25) :3603-3613.
  • 6Glennie MJ, French RR, Cragg MS, et al. Mechanisms of killing by anti-C1)20 monclonal antibodies[ J]. Mol Immunol, 2007,44(16) :3823- 3837.
  • 7Mounier N, Bfiere J, Gisselbrecht C, et al. Rituxlmab plus CHOP (R-CHOP) overcomes Bcl-2-associated resistance to chemotherapy in eld- erly patients with diffuse large B-cell lymphoma (DLBCL) [J]. Blood, 2003,101 ( 11 ) :42794284.
  • 8McLaulhlin P, Hagemeister FB, Grillo-Ltipez M. Rituximab in indo- lent lymphoma : the single-agent pivotal trial[ J ]. Semin Oncol, 1999,26 (5 Suppl 14) :79-87.
  • 9Shaw T, Quan J, Totoritis MC. 8 cell therapy for rheumatoid arthri- tis: the ritmdmab (anfi-CD20) experience[J]. Ann Rheum Dis, 2003,62(Suppl 2) : ii55-ii59.
  • 10Sehn LH, Donaldson J, Chhanabhai M, ctal. Introduction oir corn- bined CHOP plus rituximab therapy dramatically improved outcome of dif-fuse large BceLl lymphoma in British ColumbiaC[J]. J Clin Oucol, 2005, 23(22) :5027-5033.

二级参考文献56

  • 1Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MINT) Group[J]. Lancet Oncol, 2006, 7(5): 379- 391.
  • 2Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de I'Adulte[J]. J Clin Oncol, 2005, 23(18): 4117-4126.
  • 3Coiffier B, Feugier P, Mounier N, et al. Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients[Meeting Abstracts][J]. J Clin Oncol, 2007, 25 (18S): 8009.
  • 4Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD 10 B-cell lymphomas: a randomized controlled trial (RICOVER-60)[J]. Lancet Oncol, 2008, 9(2): 105- 116.
  • 5Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and eyelophosphamide, doxorubicin, vineristine, and prednisoue significantly improves response and time to treatment failure, but not long-term outcome in patients with previouslyuntreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)[J]. J Clin Oncol, 2005, 23(9):1984-1992.
  • 6Hainsworth JD, Litchy S, Burris HA 3rd, et al. Rituximab as firstline and maintenance therapy for patients with indolent non-Hodgkin's lymphoma[J]. J Clin Oncol, 2002, 20(20): 4261-4267.
  • 7Ghiehnini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly×4 schedule[J]. Blood, 2004, 103(12): 4416- 4423.
  • 8Gordan LN, Grow WB, Pusateri A, et al. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders[J]. J Clin Oncol, 2005, 23(6): 1096- 1102.
  • 9Hagenbeek A, Van Glabbeke M, Teodorovic I, et al. The role of rituximab maintenance treatment in relapsed follicular NHL: in interim analysis of the EORTC randomized intergroup trial[Meeting Abstracts]. Ann Oncol, 2005, 16: v52. Abstract 61.
  • 10Morrison VA, Weller EA, Habermann TM, et al. Maintenance rituximab (MR) compared to observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL): an Intergroup E4494/C9793 update[Meeting Abstracts]. J Clin Oncol. 2007, 25(18S): 8011.

共引文献36

放射免疫学杂志
2011年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部